These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21512094)

  • 21. An exploratory study into the role of dynamic contrast-enhanced (DCE) MRI metrics as predictors of response in head and neck cancers.
    Agrawal S; Awasthi R; Singh A; Haris M; Gupta RK; Rathore RK
    Clin Radiol; 2012 Sep; 67(9):e1-5. PubMed ID: 22583950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Schubert EK; Tseng J; Lawton TJ; Linden HM; Livingston RB
    J Nucl Med; 2003 Nov; 44(11):1806-14. PubMed ID: 14602864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients.
    Choi HK; Cho N; Moon WK; Im SA; Han W; Noh DY
    Eur J Radiol; 2012 Apr; 81(4):737-43. PubMed ID: 21300498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
    Rosen EL; Blackwell KL; Baker JA; Soo MS; Bentley RC; Yu D; Samulski TV; Dewhirst MW
    AJR Am J Roentgenol; 2003 Nov; 181(5):1275-82. PubMed ID: 14573420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
    Loo CE; Teertstra HJ; Rodenhuis S; van de Vijver MJ; Hannemann J; Muller SH; Peeters MJ; Gilhuijs KG
    AJR Am J Roentgenol; 2008 Nov; 191(5):1331-8. PubMed ID: 18941065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
    Craciunescu OI; Blackwell KL; Jones EL; Macfall JR; Yu D; Vujaskovic Z; Wong TZ; Liotcheva V; Rosen EL; Prosnitz LR; Samulski TV; Dewhirst MW
    Int J Hyperthermia; 2009; 25(6):405-15. PubMed ID: 19657852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
    Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
    Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Preoperative evaluation of pathologic response in patients with breast cancer by dynamic contrast-enhanced magnetic resonance imaging].
    Zhang XP; Li J; Sun YS; Cao K; Tang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Feb; 30(1):98-103. PubMed ID: 18361063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance.
    Andersen EK; Hole KH; Lund KV; Sundfør K; Kristensen GB; Lyng H; Malinen E
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e485-92. PubMed ID: 22014954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-dimensional vascular mapping of the breast by using contrast-enhanced MRI: association of unilateral increased vascularity with ipsilateral breast cancer.
    Orgüç Ş; Başara I; Coşkun T; Pekindil G
    Diagn Interv Radiol; 2012; 18(5):454-9. PubMed ID: 22865198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast.
    Drew PJ; Kerin MJ; Mahapatra T; Malone C; Monson JR; Turnbull LW; Fox JN
    Eur J Surg Oncol; 2001 Nov; 27(7):617-20. PubMed ID: 11669587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Drucker MJ; Livingston RB
    Cancer; 1999 Jun; 85(11):2410-23. PubMed ID: 10357412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy.
    Dongfeng H; Daqing M; Erhu J
    Clin Breast Cancer; 2012 Apr; 12(2):94-101. PubMed ID: 22169574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
    J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
    Schrier BP; Peters M; Barentsz JO; Witjes JA
    Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.